NCT07389499: A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

Sponsor: Grit Biotechnology. Phase: EARLY_PHASE1. Conditions: IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN), Refractory Podocytopathy, Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits